Knopp Biosciences announces oral candidate drug dexpramipexole for FDA orphan drug designation

high eosinophil syndrome (HES) mainly refers to the patient's blood the number of eosinophils continued to increase (the absolute number of eosinophils is greater than 0.5 x 109/L), clinical manifestations of fever, asthma, abdominal pain, spleen swelling, vascular neuroedema and other symptoms, different etiology caused by complications are not the sameAt present, the exact cause of the disease has not yet been determinedApril 24http://
http://
http://
http://
(
In the United States, fewer than 200,000 people suffer from highly acidophilic granulocytic syndromeThe FDA's identification of dexpramipexole's orphan drug has established the drug's special status in this fieldKnopp Biosciences, as the drug's developer, received federal grants, tax credits, and exemptions from PDUFA application fees, as well as a seven-year marketing exclusive period for the drugDexpramipexole' efficacy as an oral drug for THE treatment of HES has been demonstrated in a number of clinicaltrial spree(http:// HeS patients in excess of eosinophils is a white blood cell, has the function of killing bacteria, parasites, but it is also asthma, acid mitochondrial hyperplasia and other diseases "behind the scenes." Dexpramipexole has demonstrated the ability to effectively reduce the level of eosinophils in blood and tissues in clinical phase 2 trials Knopp Biosciences has presented the findings to the American Society of Hematology and published in the Journal of Blood Knopp Biosciences Knopp Biosciences is a pharmaceutical research and development company co-founded in 2005 by Dr Gregory Hebrank and Dr Robert Bowser Focusing on diseases in the nervous system, the company is dedicated to providing breakthrough treatments for patients with inflammatory and neurological disorders to meet the needs of the highly unmet medical (http:// Now, Knopp Biosciences has developed a small molecular media discovery platform for epilepsy and neuropathic pain, and has developed a research compound for the treatment of immune and blood diseases